Eighteen months ago, Intellia Therapeutics was in trouble.

The MAGNITUDE Phase 3 trial had a Grade 4 liver event. Dosing got paused, the stock dropped, and by January 2025, the company had cut 27% of its workforce and discontinued the alpha-1 antitrypsin program to extend runway.

Now they’re filing the first systemic in vivo CRISPR BLA in history.

Intellia just reported that the HAELO Phase 3 trial of lonvoguran ziclumeran hit its primary endpoint and all key secondary endpoints in hereditary angioedema.

The single-dose CRISPR therapy permanently inactivates the KLKB1 gene in the liver, knocking down kallikrein production and downstream bradykinin … these are the proteins that cause HAE attacks (swelling of the hands, face, throat, abdomen, feet – super dangerous).

This thing PERMANENTLY edits the genome… so, a single dose does the trick.

Earlier Phase 2 data showed a 98% mean reduction in monthly attacks across patients, with median attack-free duration of 23 months from a single infusion.

If that durability holds in Phase 3, this changes the entire HAE treatment paradigm.

Why this matters beyond Intellia: the in vivo CRISPR thesis has been the holy grail of gene editing for almost a decade.

Skip ex vivo cell manufacturing entirely. Inject the editing machinery into the patient. Let it find the target tissue, make the edit, and dissolve.

It works on paper and everyone is going absolutely BANANAS right now over in vivo CAR-T, but the clinical translation has been much harder.

Off-target effects matter more.

Delivery has to find the right tissue.

Immune responses to LNPs and Cas9 protein are real concerns.

Intellia’s lipid nanoparticle delivery platform can also be redosed if needed, which is something viral vector approaches struggle with. The HAE data showing patients attack-free for almost two years from one infusion suggests durability isn’t the failure mode here.

This isn’t the only signal that the gene editing field is maturing. We’ve covered 2 really interesting stories in this space in the last week or so:

Metagenomi has built a 488-amino-acid CRISPR small enough to fit inside an AAV.

SNIPR Biome has shown CRISPR can work as a precision antibiotic.

The whole modality is fragmenting into specialized approaches, each tackling different therapeutic problems.

But Intellia is about to do the thing none of them have done yet.

An approval will finally validate everyone in the field.

If lonvo-z hits in H1 2027, suddenly every in vivo gene editing pitch deck gets taken more seriously and every IND filing has a precedent to point to.

Eighteen months ago this looked like a company in trouble.

Now it might be the one that opens the door.